<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Interferon gamma-1b: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Interferon gamma-1b: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Interferon gamma-1b: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11496" href="/d/html/11496.html" rel="external">see "Interferon gamma-1b: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F183604"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Actimmune</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F183622"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Interferon</li></ul></div>
<div class="block doa drugH1Div" id="F183607"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing expressed in mcg; 50 mcg is equivalent to 1 million units (50 mcg/m<sup>2</sup> is equivalent to 1 million units/m<sup>2</sup>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e3ff7016-55f0-4ee2-bdf8-93780d7b608a">Chronic granulomatous disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic granulomatous disease:</b>
<b>SUBQ:</b> 50 mcg/m<sup>2</sup> (1 million units/m<sup>2</sup>) 3 times weekly; maximum dose: 50 mcg/m<sup>2</sup></p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3a6bfda0-8abd-42db-a040-dc1dd533d2dd">Malignant osteopetrosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malignant osteopetrosis (severe):</b>
<b>SUBQ:</b> 50 mcg/m<sup>2</sup> (1 million units/m<sup>2</sup>) 3 times weekly; maximum dose: 50 mcg/m<sup>2</sup></p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990696"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; drug accumulation may occur in patients with severe renal insufficiency.</p></div>
<div class="block doha drugH1Div" id="F50988022"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; drug accumulation may occur in patients with advanced hepatic disease. If severe transaminase elevations occur during treatment, interrupt and reduce the dose upon resolution.</p></div>
<div class="block dot drugH1Div" id="F2934668"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;text-align:justify;display:inline">If severe reactions occur, reduce dose by 50% or therapy should be interrupted until adverse reaction abates.</p></div>
<div class="block doe drugH1Div" id="F183608"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F183617"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing expressed in mcg; 50 mcg is equivalent to 1 million units (50 mcg/m<sup>2</sup> is equivalent to 1 million units/m<sup>2</sup>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e3ff7016-55f0-4ee2-bdf8-93780d7b608a">Chronic granulomatous disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic granulomatous disease:</b> Children and Adolescents: SUBQ:</p>
<p style="text-indent:-2em;margin-left:4em;">Body surface area (BSA) ≤0.5 m<sup>2</sup>: 1.5 mcg/kg/dose 3 times weekly; maximum dose: 50 mcg/m<sup>2</sup></p>
<p style="text-indent:-2em;margin-left:4em;">BSA &gt;0.5 m<sup>2</sup>: 50 mcg/m<sup>2</sup> (1 million units/m<sup>2</sup>) 3 times weekly; maximum dose: 50 mcg/m<sup>2</sup></p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3a6bfda0-8abd-42db-a040-dc1dd533d2dd">Malignant osteopetrosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malignant osteopetrosis (severe):</b> Infants, Children, and Adolescents: SUBQ:</p>
<p style="text-indent:-2em;margin-left:4em;">Body surface area (BSA) ≤0.5 m<sup>2</sup>: 1.5 mcg/kg/dose 3 times weekly; maximum dose: 50 mcg/m<sup>2</sup></p>
<p style="text-indent:-2em;margin-left:4em;">BSA &gt;0.5 m<sup>2</sup>: 50 mcg/m<sup>2</sup> (1 million units/m<sup>2</sup>) 3 times weekly; maximum dose: 50 mcg/m<sup>2</sup></p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosing adjustment for toxicity:</b> Infants, Children, and Adolescents: If severe reactions occur, reduce dose by 50% or therapy should be interrupted until adverse reaction abates.</p></div>
<div class="block dorp drugH1Div" id="F51113906"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; drug accumulation may occur in patients with severe renal insufficiency.</p></div>
<div class="block dohp drugH1Div" id="F51113907"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; drug accumulation may occur in patients with advanced hepatic disease. If severe transaminase elevations occur during treatment, interrupt and reduce the dose upon resolution.</p></div>
<div class="block adr drugH1Div" id="F183581"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Based on 50 mcg/m<sup>2</sup> dose administered 3 times weekly for chronic granulomatous disease</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Fever (52%), headache (33%), chills (14%), fatigue (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Rash (17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (14%), vomiting (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site erythema or tenderness (14%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Depression (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (10%), abdominal pain (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia (6%), arthralgia (2%), back pain (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Alkaline phosphatase elevated, atopic dermatitis, granulomatous colitis, hepatomegaly, hypersensitivity reactions, hypokalemia, neutropenia, Stevens-Johnson syndrome</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Additional adverse reactions noted at doses &gt;100 mcg/m<sup>2</sup> administered 3 times weekly: ALT increased, AST increased, autoantibodies increased, bronchospasm, chest discomfort, confusion, dermatomyositis exacerbation, disorientation, DVT, gait disturbance, GI bleeding, hallucinations, heart block, heart failure, hepatic insufficiency, hyperglycemia, hypertriglyceridemia, hyponatremia, hypotension, interstitial pneumonitis, lupus-like syndrome, MI, neutropenia, pancreatitis (may be fatal), Parkinsonian symptoms, PE, proteinuria, renal insufficiency (reversible), seizure, syncope, tachyarrhythmia, tachypnea, thrombocytopenia, TIA</p></div>
<div class="block coi drugH1Div" id="F183593"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to interferon gamma, <i>E. coli</i> derived products, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F183578"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Dose-related reversible neutropenia and thrombocytopenia (may be severe) have been reported; use caution in patients with myelosuppression.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: Neurologic disorders (ie, decreased mental status, gait disturbances, dizziness) have been noted at the higher doses (&gt;250 mcg/m<sup>2</sup>/day); most of these abnormalities were reversible within a few days after dose reduction or discontinuation. Use with caution in patients with a history of seizure disorder or compromised CNS function.</p>
<p style="text-indent:-2em;margin-left:4em;">• Flu-like symptoms: Acute and transient flu-like symptoms (eg, fever, headache, chills, myalgia, fatigue) have been noted at the higher doses (&gt;250 mcg/m<sup>2</sup>/day) and may exacerbate preexisting cardiovascular disorders; some of the flu-like symptoms may be minimized by bedtime administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Elevations of AST and/or ALT (up to 25-fold) have been observed and were reversible with dose reduction or interruption of treatment. Incidence may be increased in children &lt;1 year; perform monthly liver function assessments in this age group; modify dosage if severe elevations of liver enzyme develop.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Acute serious hypersensitivity reactions have been reported (case reports); transient cutaneous rashes may occur; treatment interruption may be necessary. Discontinue therapy immediately if an acute reaction occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with preexisting cardiovascular disease, including ischemia, heart failure, or arrhythmia. In a scientific statement from the American Heart Association, interferon has been determined to be an agent that may either cause reversible direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: moderate/major) (AHA [Page 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic function impairment: Drug accumulation may occur in patients with advanced hepatic disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal function impairment: Drug accumulation may occur in patients with severe renal insufficiency; renal toxicity has been reported.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Latex: The vial stopper may contain dry natural rubber and may cause allergic reactions.</p></div>
<div class="block dosfc drugH1Div" id="F28842879"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Actimmune Injection, solution: 100 mcg (2 million units) per 0.5 mL (50 mcg is equivalent to 1 million units)</p></div>
<div class="block foc drugH1Div" id="F183588"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Actimmune: 2,000,000 units/0.5 mL (0.5 mL)</p></div>
<div class="block geq drugH1Div" id="F183575"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323199"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Actimmune Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2000000 units/0.5 mL (per 0.5 mL): $6,513.68</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F4419053"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">SubQ: Administer by SubQ injection into the right and left deltoid or anterior thigh. Consider premedication with acetaminophen and/or bedtime administration to minimize adverse reactions (eg, flu-like symptoms). Do not mix with other drugs in the same syringe.</p></div>
<div class="block admp drugH1Div" id="F52613065"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">SubQ: Administer by SubQ injection into the right and left deltoid or anterior thigh. Consider premedication with acetaminophen and/or bedtime administration to minimize adverse reactions (eg, flu-like symptoms). Do not mix with other drugs in the same syringe.</p></div>
<div class="block use drugH1Div" id="F183589"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic granulomatous disease:</b> Reduction in the frequency and severity of serious infections associated with chronic granulomatous disease</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Malignant osteopetrosis (severe): </b> To delay time to disease progression in patients with severe, malignant osteopetrosis</p></div>
<div class="block cyt drugH1Div" id="F183618"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F183582"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Zidovudine: Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F183594"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have been observed in animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F183595"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if interferon gamma 1b is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F183586"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential, platelets, LFTs (monthly in children &lt;1 year), electrolytes, BUN, creatinine, and urinalysis prior to therapy and at 3-month intervals</p></div>
<div class="block pha drugH1Div" id="F4418991"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Interferon gamma participates in immunoregulation by enhancing the oxidative metabolism of macrophages; it also enhances antibody dependent cellular cytotoxicity, activates natural killer cells and has a role in the expression of Fc receptors and major histocompatibility antigens.</p></div>
<div class="block phk drugH1Div" id="F183592"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: IM, SubQ: &gt;89%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: IM: ~3 hours, SubQ: ~6 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, plasma: IM: ~4 hours (1.5 ng/mL); SubQ: ~7 hours (0.6 ng/mL)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F183596"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Imukin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Imukin</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Imukin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Immukine</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Imukin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Imukin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Imukin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Imukin</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Immukin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Immukin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Immukin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Imukin</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Imukin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Actimmune</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Imukin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Imukin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Immukine</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Immukine | Imukin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Imukin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Imukin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Actimmune</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Imukin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Imukin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Imukin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Imukin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Imukin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Imukin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Actimmune injection, subcutaneous (interferon gamma-1b) [prescribing information]. Deerfield, IL: Horizon Therapeutics USA Inc; March 2021.</div>
</li>
<li>
<div class="reference">
                  Actimmune solution for injection (interferon gamma-1b) [prescribing information]. Lake Forest, IL: HZNP USA; July 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7753137">
<a name="7753137"></a>Key LL, Rodriguiz RM, Willi SM, et al, “Long-Term Treatment of Osteopetrosis With Recombinant Human Interferon Gamma,” <i>N Engl J Med</i> 1995, 332(24):1594-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-gamma-1b-drug-information/abstract-text/7753137/pubmed" id="7753137" target="_blank">7753137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15356785">
<a name="15356785"></a>Marciano BE, Wesley R, DeCarlo E, et al, “Long-Term Interferon-Gamma Therapy for Patients With Chronic Granulomatous Disease,” <i>Clin Infect Dis</i>, 2004, 39(5):692-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-gamma-1b-drug-information/abstract-text/15356785/pubmed" id="15356785" target="_blank">15356785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-gamma-1b-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8987 Version 161.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
